CJC-1295 No-DAC vs Tesamorelin: Both GHRH Analogs, Very Different Evidence Bases

CJC-1295 no-DAC (modified GRF 1-29) and tesamorelin are both synthetic GHRH analogs that bind the GHRH receptor on pituitary somatotrophs to stimulate pulsatile GH release. Their shared mechanism makes them pharmacologically similar in principle, but their real-world profiles diverge substantially in half-life, evidence base, cost, and clinical use.

CJC-1295 no-DAC has a plasma half-life of approximately 30 minutes. It requires subcutaneous injection and is almost always paired with a GHRP (typically ipamorelin) to produce a complete GH pulse. Without a GHRP co-trigger, the GH response to GHRH alone is submaximal because endogenous ghrelin must provide the trigger signal. The compound is available only on the grey market, with no regulatory approval or formal prescribing data.

Tesamorelin is a stabilised synthetic GHRH analog with a longer effective duration due to its modified structure. It is FDA-approved (June 2010) for HIV-associated lipodystrophy (excess visceral fat in HIV patients on antiretroviral therapy). The pivotal Phase 3 program (Falutz et al., 2010, PMID 20554713) randomised 806 patients to daily tesamorelin 2 mg subcutaneous versus placebo for 26 to 52 weeks, producing the largest controlled human trial of any GHRH analog. This trial provides the most reliable human evidence available for what daily GHRH-analog stimulation produces in terms of body composition, IGF-1, lipids, and glucose.

The tesamorelin Phase 3 data is the best available clinical benchmark for predicting what CJC-1295 no-DAC might do in an equivalent context. The key difference is that tesamorelin is used daily as a standalone agent, while CJC-1295 no-DAC is used 1 to 3 times daily with ipamorelin for discrete pulses.

Half-life and dosing:

• CJC-1295 no-DAC: plasma half-life approximately 30 minutes; requires 1 to 3 injections per day; needs ipamorelin co-administration for maximum GH pulse amplitude
• Tesamorelin: has a longer effective biological duration due to its structural modification (trans-3-hexenoic acid conjugate) that protects it from DPP-IV degradation; single daily injection as monotherapy is the approved protocol

Evidence base:

• CJC-1295 no-DAC: no human RCT; grey market compound; mechanistic extrapolation from GHRH-class data
• Tesamorelin: FDA-approved 2010; Phase 3 RCT (Falutz 2010) in 806 patients over 26 to 52 weeks; post-marketing safety data from clinical use

Visceral fat reduction (the Falutz 2010 landmark data):

• Tesamorelin 2 mg/day vs placebo over 26 weeks: visceral adipose tissue reduced by 15.4 percentage points more than placebo (the primary endpoint)
• Treatment effect confirmed durable at 52 weeks
• CJC-1295 no-DAC: no controlled visceral fat data; mechanistic expectation of similar fat reduction based on shared GHRH pathway, but magnitude uncertain

Triglycerides (Falutz 2010):

• Tesamorelin 2 mg/day: triglycerides fell 37 mg/dL versus placebo at 26 weeks and 48 mg/dL at 52 weeks; statistically significant and clinically meaningful
• CJC-1295 no-DAC: no controlled lipid data; GHRH-class mechanism predicts similar directional effects

Cholesterol to HDL ratio (Falutz 2010):

• Tesamorelin: improved 7.2% versus placebo at 52 weeks; a meaningful cardiovascular risk marker improvement
• CJC-1295 no-DAC: neutral to mildly favourable expected based on tesamorelin proxy data

IGF-1 elevation (Falutz 2010):

• Tesamorelin 2 mg/day: IGF-1 rose 108 ng/mL above placebo at 26 weeks (absolute change)
• CJC-1295 no-DAC plus ipamorelin: 20 to 60% elevation at standard doses; magnitude depends on dose, injection frequency, and individual GH secretory reserve

Glucose and insulin sensitivity (Falutz 2010):

• Tesamorelin: no statistically significant change in fasting glucose or HbA1c across 806 patients over 52 weeks
• CJC-1295 no-DAC: expected to share this glucose-neutral profile based on the pulsatile GHRH mechanism

Cost:

• CJC-1295 no-DAC (grey market): approximately USD $30 to $80 per month for the GHRH component alone; add USD $30 to $70 for ipamorelin
• Tesamorelin (brand name Egrifta): USD $2,000+ per month brand; limited generic availability; occasionally found on grey market at lower cost but less reliably than peptide research chemicals

Regulatory and safety status:

• CJC-1295 no-DAC: unregulated grey market research chemical; no dosing guidance, purity standards, or post-marketing safety surveillance
• Tesamorelin: FDA-approved drug with prescribing information, contraindications (active malignancy, pregnancy), documented safety profile, and post-marketing pharmacovigilance

Choose CJC-1295 no-DAC (plus ipamorelin) if:

• Cost is a primary barrier; CJC-1295 no-DAC is dramatically cheaper than brand tesamorelin
• You want the flexibility of pairing a GHRH analog with ipamorelin for a customisable pulse protocol
• You are comfortable with grey market research chemical sourcing and associated quality risks
• Your primary goal is IGF-1 elevation and pulsatile GH optimisation rather than specifically documented visceral fat reduction
• You are managing a multi-compound protocol where the 1 to 3 times daily peptide injection schedule integrates easily

Choose tesamorelin if:

• Evidence quality matters: you want the compound with the largest controlled human trial supporting its effects
• Visceral fat reduction is a specific goal; the 15.4% visceral fat reduction endpoint in the Phase 3 trial is the strongest human evidence for any GHRH analog's fat-loss efficacy
• You have HIV-associated lipodystrophy, which is the approved indication
• You have access to pharmaceutical-grade tesamorelin through a prescription or a high-quality grey market source
• You are over 40, have metabolic syndrome, or have significant hepatic steatosis; the tesamorelin data provides more clinical confidence in outcomes than CJC-1295 no-DAC extrapolation
• You prefer single daily injection over multiple injections per day

For bodybuilders without HIV lipodystrophy:

• CJC-1295 no-DAC plus ipamorelin is the practical choice due to cost and flexibility
• Tesamorelin is the choice when the Phase 3 evidence base is specifically required for decision-making confidence or when visceral fat is a primary documented concern